RedHill Biopharma (RDHL) Free Cash Flow (2012 - 2022)

RedHill Biopharma (RDHL) has 11 years of Free Cash Flow data on file, last reported at -$2.4 million in Q4 2022.

• On a quarterly basis, Free Cash Flow rose 83.7% year-over-year to -$2.4 million in Q4 2022; TTM through Dec 2023 was -$2.4 million, a 91.65% increase from a year earlier, with the FY2025 full-year figure at -$9.6 million, down 3.06% from the prior year.
• Free Cash Flow for Q4 2022 stood at -$2.4 million, up from -$6.0 million in the prior quarter.
• Over the last five years, Free Cash Flow for RDHL reached as high as -$2.4 million in Q4 2022 and fell as low as -$19.0 million in Q3 2021.
• Historically, Free Cash Flow has averaged -$10.8 million across 5 years, with a median of -$9.9 million in 2018.
• Across the five-year window, Free Cash Flow slumped 111.04% in 2021 and jumped 83.7% in 2022, its largest moves.
• Year by year, Free Cash Flow stood at -$8.2 million in 2018, then sank by 68.96% to -$13.8 million in 2019, then rose by 8.53% to -$12.7 million in 2020, then fell by 17.38% to -$14.9 million in 2021, then soared by 83.7% to -$2.4 million in 2022.
• Per Business Quant data, the three most recent Free Cash Flow figures were -$2.4 million in Q4 2022, -$6.0 million in Q3 2022, and -$16.4 million in Q2 2022.